Breast Cancer After Hodgkin Disease

Yahalom, Joachim

doi:10.1001/jama.290.4.529

Cited by 26 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a thoughtful editorial, Yahalom (39) concluded that the results of the international study (16) implied that the smaller radiotherapy fields and lower doses now used to treat Hodgkin lymphoma should eventually result in lower risks of breast cancer. Before the publication of these studies (16,17), there had been no convincing evidence to suggest that recent treatment modifications for Hodgkin lymphoma might translate into decreased long-term risks of solid tumors.…”

Section: Therapy-associated Solid Tumorsmentioning

confidence: 99%

The Epidemiology of Second Primary Cancers

Travis

2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

266

220

View full text Add to dashboard Cite

Background: Due to improvements in early detection, supportive care, and treatment, the number of cancer survivors in the United States has tripled since 1971 and is growing by 2% each year. In 2001, there were f10 million cancer survivors, representing 3.5% of the population. As survival after a diagnosis of cancer improves, quantification of the late effects of cancer and its therapy become critical. One of the most serious events experienced by cancer survivors is the diagnosis of a new cancer. Second-or higher-order cancers now account for f16% of incident cancers reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Subsequent neoplasms may not necessarily be attributable to prior cancer treatment but may also reflect the effect of shared etiologic factors, environmental exposures, host characteristics, and combinations of influences, including gene-environment and gene-gene interactions.

show abstract

Section: Therapy-associated Solid Tumorsmentioning

confidence: 99%

The Epidemiology of Second Primary Cancers

Travis

2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

266

220

View full text Add to dashboard Cite

show abstract

“…Most breast cancer lesions in female survivors of Hodgkin disease are ductal carcinomas in situ or infi ltrating carcinomas (Bhatia et al, 1996;Cutuli et al, 1997;Diller et al, 2002;Kaste et al, 1998;Neglia et al, 2001). Breast tumors occur at the margin or in the fi eld of irradiated tissue (Yahalom, 2003).…”

Section: Literature Review and Theoretical Framework Breast Cancer Afmentioning

confidence: 99%

“…The potential carcinogenic role of each of these factors alone or in combination has been debated (Deniz, O'Mahony, Ross, & Purushotham, 2003;Kenney et al, 2004;Tinger et al, 1997;van Leeuwen et al, 2003). Yahalom (2003) argued that the increased risk of breast cancer in female survivors of Hodgkin disease undoubtedly is associated with use of radiation therapy. Radiation therapy has been a standard treatment for Hodgkin disease since the 1960s.…”

Section: Literature Review and Theoretical Framework Breast Cancer Afmentioning

confidence: 99%

Creating the Basis for a Breast Health Program for Female Survivors of Hodgkin Disease Using a Participatory Research Approach

Crom¹,

Hinds²,

Gattuso³

et al. 2005

Oncology Nursing Forum

View full text Add to dashboard Cite

show abstract

“…The optimal treatment strategy is still evolving and is, at times, spiritedly debated. [1][2][3][4][5][6][7] The bottom-line question is, how much further can we reduce the treatment to avoid long-term complications without reducing the long established high cure rate? Furthermore, because more than one option of reasonably effective therapy and a salvage option may be available, what should be regarded as the current standard of care and which alternatives should be studied in future trials?…”

mentioning

confidence: 99%

Favorable Early-Stage Hodgkin Lymphoma

Yahalom

2006

J Natl Compr Canc Netw

Self Cite

View full text Add to dashboard Cite

The category of favorable early-stage Hodgkin lymphoma (HL) includes patients with Ann Arbor stages I or II disease with no bulky disease or B symptoms. The precise definition of favorable versus unfavorable early-stage disease may vary among American and European cooperative groups. The overall 10-year survival rate of patients with favorable early-stage HL exceeds 90%. Indeed, effective treatments for this group of patients have been available for more than 4 decades. However, treatment strategies have radically changed over the past 15 years and focus now on maintaining the high cure rate while reducing the risk of treatment-related long-term morbidity. The optimal treatment is still evolving, and more recently, reduction in the total amount of chemotherapy and in radiation field and dose has shown excellent results. Combined modality therapy is the preferred treatment for patients with classical favorable early-stage HL (nodular sclerosis or mixed cellularity histology). Patients with early-stage lymphocyte predominance HL are highly curable using involved-field radiation therapy (IFRT) alone and do not require chemotherapy. Classical favorable HL is also curable with radiotherapy alone or with chemotherapy alone, but larger fields and higher-dose radiation or longer chemotherapy is required compared with combined modality. The freedom from treatment failure rate is significantly better with a combination of short chemotherapy and IFRT than with either chemotherapy or radiotherapy alone. Although combined modality is the standard preferred treatment for favorable disease, radiation therapy alone or chemotherapy alone could be considered under special circumstances or as part of an investigational protocol.

show abstract

Breast Cancer After Hodgkin Disease

Cited by 26 publications

References 18 publications

The Epidemiology of Second Primary Cancers

The Epidemiology of Second Primary Cancers

Creating the Basis for a Breast Health Program for Female Survivors of Hodgkin Disease Using a Participatory Research Approach

Favorable Early-Stage Hodgkin Lymphoma

Contact Info

Product

Resources

About